The advent of gene therapy as a viable therapeutic approach has given impetus for development of vector systems, such as mammalian artificial chromosomes that may provide safer and more efficient means of delivering genes to affected individuals. Potential advantages of a mammalian artificial chromosome vector include the greater stability and safety of autonomously replicating, non-integrating chromosomes in mammalian cells, a lower likelihood of immune responses directed against these chromosomes, as well as increased carrying capacity over existing systems that would broaden the scope of candidate indications for gene therapy. One approach used to generate mammalian artificial chromosomes involves induction of de novo chromosome formation in mammalian cells by eliciting large scale amplification in a region proximal to the pericentric heterochromatin following introduction of exogenous DNA into an existing acrocentric chromosome, resulting in duplication of the centromere (reviewed recently in Hadlaczky 1 ). A new artificial chromosome (termed artificial chromosome expression system or ACes) is formed from an ensuing cleavage of this dicentric chromosome. ACes are typically 40-80 Mb in size and are composed predominantly of satellite repeat sequences, interspersed with sub-domains of co-amplified transfected foreign DNA which may also contain co-amplified endogenous rDNA. This process reproducibly gives rise to murine and human ACes that can be readily purified 2 and are efficiently transferred to new cell lines. 3 Moreover the long-term stability of ACes generated in this manner has been demonstrated in cell lines 4 and transgenic animals. 5 In order to enhance the use of ACes, it would be advan- tageous to modify them so that genes of interest could be added more efficiently and reproducibly. Moreover, the potential ability to subsequently remove and/or replace genes would allow for reuse of such modified ACes. These goals could be achieved by integrating sitespecific recombination systems such as Cre-Lox, 6 or FLP-FRT, 7 on to a pre-existing ACes. We report here the generation and subsequent retrofitting of a murine ACes with loxP recombination sites using an approach that does not rely on drug selection.
An ACes was generated in LMTK Ϫ cells using the methodology previously described. [8] [9] [10] Briefly, transfection of LMTK Ϫ cells was carried out with the linearised pFKPuro construct (containing a portion of a mouse rDNA gene, shown in Figure 1a ) and puromycin-resistant subclones were analyzed by fluorescent in situ hybridization (FISH). In two clones out of 24 analyzed, integration of the transgene elicited large-scale amplifications proximal to pericentric heterochromatin. Further subcloning of one of the clones gave rise to a homogeneous cell line (designated 5B11-12) containing a putative ACes (Figure 1b) , consisting predominantly of sequences associated with murine centromeric heterochromatin, such as the mouse major (Figure 1b and d) and mouse minor satellite repeats (Figure 1g ), while telomere repeats could be detected at the distal tips of the chromosome arms, suggesting a linear structure (data not shown). In addition, two extended regions of strong pFKPuro hybridization were detected on the ACes (Figure 1b, e, f) .
By virtue of their size and composition, ACes are amenable to purification using flow cytometry. 2 As can be seen in the flow karyogram (Figure 1i ), a unique peak (R1) could readily be distinguished from the bulk of 5B11-12 chromosomes. In all other respects the flow karyograms of wild-type LMTK Ϫ (Figure 1h ) and 5B11-12
Gene Therapy cells ( Figure 1i ) were identical. Analysis of the R1 peak by FISH showed it to consist exclusively of ACes ( Figure  1f ). Thus purification of 5B11-12 ACes to virtual homogeneity was achieved using flow cytometry. While loxP recombination sites could have been introduced on to the ACes during de novo biosynthesis, it was thought that this might result in multiple segments of the ACes containing a high number of loxP sites, leading to instability upon Cre-mediated recombination. A gene targeting approach was therefore devised to introduce a more limited number of loxP recombination sites into a locus of the 5B11-12 ACes containing introduced and possibly co-amplified endogenous rDNA sequences. Although there are more than 200 copies of rDNA genes in the haploid mouse genome distributed amongst 5-11 chromosomes (depending on strain), 11, 12 we chose to target the introduced rDNA sequences on the ACes since they represent a less frequent target than that of the satellite repeat sequences. Moreover, having observed much stronger pFKPuro hybridization to the 5B11-12 ACes than to other LMTK Ϫ chromosomes (see Figure 1b ) and in light of the observation that at least a part of the transcribed spacer sequences within the rDNA may be less conserved than the rRNA coding regions (Fodor, Cserpan and Hadlaczky, unpublished data), we speculated that a targeting vector based on the rDNA gene in pFKPuro would have a higher probability of targeting to the ACes rather than to other LMTK Ϫ chromosomes. Accordingly, a targeting vector was designed and constructed based on the rDNA sequences contained in pFKPuro (see Figure 2 for details) . We also wanted to test the feasibility of a more general targeting strategy that would not rely on enrichment via drug selection of stably transfected clones. Therefore a red fluorescent protein gene (RFP; encoded by the DsRed gene) was inserted between the loxP sites of the targeting vector. Sequential rounds of high speed flow sorting and expansion of sorted cells in culture could then be used to enrich for stable transformants expressing RFP (use of GFP as a selectable marker for enrichment of stable GFP-expressing trans-formants has also been described 13 ). PCR screening with a PCR primer that amplifies from a spacer region within the 45S pre-rRNA gene in pFKPuro (Figure 1 ) to a specific anchor sequence within the DsRed gene in the targeting cassette generates a 2.3 kb fragment diagnostic of a targeting event. However, as rDNA clusters are found on several chromosomes, confirmation of targeting to an ACes would require fluorescence in situ hybridization (FISH) analysis. Finally the flanking of the DsRed gene by loxP sites would allow for its removal and subsequent replacement with other genes of interest.
After transfection of the targeting sequence into 5B11-12 cells, enrichment for targeted clones was carried out using a combination of flow cytometry to detect red-fluorescing cells and PCR screening. Ultimately 17 single cell subclones were identified as potential targeted clones by PCR and of these 16 were found by FISH to contain DsRed integrations on the ACes (data not shown). An example of one such subclone, D11-C4, is shown in Figure 2b-f . PCR analysis of genomic DNA isolated from the D11-C4 subclone gave rise to a 2. . Despite the low frequency of these events in mammalian cells, it is clear that an RFP expression-based screening paradigm, coupled with PCR analysis, can effectively detect and enrich for such infrequent events in a large population. In instances where drug selection is not possible or not desirable, such a system may provide a useful alternative. We also verified that the modified ACes in subclone D11-C4 could be purified by flow cytometry. As can be seen in Figure 2f , the flow karyogram of the D11-C4 subclone was unaltered from that of the 5B11-12 cell line (Figure 1i) . Thus, the D11-C4 ACes can be purified in high yield from native chromosomes of the host cell line. Figure) Figure 1h and The strong hybridization signal detected by FISH on the ACes using the DsRed gene probe suggests that several copies of the targeting cassette may be present on the ACes in the D11-C4 line. This could suggest that multiple rDNA genes have been correctly targeted. However, we cannot formally rule out that additional, non-targeted copies have also integrated within the vicinity of the targeted loci and this remains the subject of ongoing investigation. If required, it should be possible to reduce the number of loxP sites on the ACes to a single site by in situ treatment with Cre recombinase, provided that the sites are co-linear. Such a process has already been described for multiple loxP-flanked integrations on a native mouse chromosome. 15 Reduction to a single loxP site on the D11-C4 ACes would result in the loss of the DsRed gene, forming the basis of a useful screen for this event.
Figure 2 Targeted integration of loxP-flanked DsRed gene on to 5B11-12 ACes. (a) Shown is the vector pBSFKLoxDsRedLox as well as the transfected 11 kb PmlI/EcoRV targeting vector fragment excised from pBSFKLoxDsRedLox (lacking~80 bp PmlI/Not1 fragment at the 5' end of the rDNA insert). As illustrated, a targeted integration into the pFKPuro derived rDNA inserts on the ACes would restore configuration of the 5' region and could be detected by PCR as described below. (b) PCR analyses of RFP-positive single cell subclone D11-C4 showing the presence of the 2.3 kb band, diagnostic for targeted integration of LoxDsRedLox on to the ACes. In all PCR analyses performed, both negative controls (DNA extracted from 5B11-12 cells) and positive controls (diluted pBSFKLoxDsRedLox plasmid or genomic DNA from RFP positive cell population (used in
In summary, we have demonstrated that it is possible to target loxP recombination sites on to existing ACes, thus potentially simplifying the task of introducing genes of interest and consequently expanding its utility as a vector. Coupled with a simple and efficient lipid-based delivery system for transfer of ACes into new host cell lines, 3 the modified ACes described above should provide an efficient system on to which genes of interest can be inserted or deleted by Cre-mediated recombination. Experiments are currently being carried out to assess the functionality and carrying capacity of loxP-containing ACes, as well as the long-term stability and transfectability of this prototype ACes platform.
